ArticleFrontiers in immunology2025
Identification of immune-related prognostic biomarkers in lung squamous cell carcinoma microenvironment.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung squamous cell carcinoma (LUSC) is a leading cause of cancer-related mortality. Although immunotherapy has recently demonstrated clinical benefits, the biological roles of immune-related genes (IRGs) in LUSC remain insufficiently understood. Methods: In this study, transcriptomic and clinical data from 493 LUSC patients were obtained from The Cancer Genome Atlas (TCGA). IRGs were identified through weighted gene co-expression network analysis, followed by univariate Cox regression and least absolute shrinkage and selection operator (LASSO) regression to screen for prognostic genes and establish a risk prediction model. The model's predictive performance was validated, and the immune landscape associated with distinct risk subgroups was systematically characterized. Expression patterns and clinical significance of the signature genes were further investigated using bioinformatics analysis, quantitative real-time PCR, Western blotting, and immunohistochemistry. Results: A total of 55 differentially expressed IRGs were identified, among which 8 genes ( Conclusion: This study establishes a novel IRGs-based prognostic signature with potential utility for risk stratification and individualized immunotherapeutic strategies in LUSC. Furthermore, it also provides valuable insights into the role of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.